Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.

@article{Bajaj2007PhaseIS,
  title={Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.},
  author={Gopal K. Bajaj and Zhe Zhang and Elizabeth L Garrett-Mayer and Renee Drew and Victoria W Sinibaldi and Roberto Pili and Samuel R Denmeade and Michael Anthony Carducci and Mario A. Eisenberger and Theodore L Deweese},
  journal={Urology},
  year={2007},
  volume={69 3},
  pages={526-31}
}
OBJECTIVES Patients with biochemical recurrence of prostate cancer after definitive or salvage local therapy in the absence of metastatic disease represent a group well suited to a novel therapeutic intervention. Imatinib mesylate (Gleevec) is a protein-tyrosine kinase inhibitor that has previously been tested in men with androgen-independent and metastatic prostate cancer. This Phase II study was undertaken to determine the safety and efficacy of imatinib mesylate in men with biochemical… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…